1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C6F83B0F1E75BEEC652582160044B7EF
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-biopharmaceutical-medical-publications-author-transitions?opendocument
18
19opendocument
203.226.254.115
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Scientific Publications

Best Practices in Biopharmaceutical Medical Publications: Author Transitions

ID: 5493


Features:

5 Info Graphics

10 Data Graphics

50+ Metrics


Pages/Slides: 22


Published: 2018


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Best Practices in Biopharmaceutical Medical Publications: Author Transitions”


STUDY OVERVIEW


Pharmaceutical and biotechnology companies rely on scientific publications to inform the medical community about new products and therapies. However, many companies encounter potential gray areas when it comes to handling author transitions to another company or institution.

Best Practices, LLC undertook benchmarking research to explore how leading pharmaceutical and biotechnology companies tackle author and KOL transitions. Specifically, this study provides insights on guidance, if any, provided by companies on the removal of an author from the publication, when an author is leaving for a competitor/non-competitor, circumstances under which former employee is allowed to remain lead author, and specification of authorship rights in employment contract.

This study will serve as a reference for medical publication leaders to shape their authorship transition guidelines.


KEY TOPICS

  • Guidance for Transitioning Authors
  • Joining a Competitor vs Non-competitor
  • Guidance for Transitioning KOLs

KEY METRICS

  • Does your company provide guidance on if/when an author changing institutions should be removed from a publication?
  • What guidance do you provide when an internal author is leaving for a competitor/non-competitor?
  • What stage does the publication have to reach to allow a former employee to remain as a lead author?
  • When can an internal author who has left your company present publication data at a congress?
  • Does your employment contract have sections that clarify authorship rights in the event of an internal author leaving your company?

SAMPLE KEY FINDINGS

  • Former employee retained as lead author
    1. For a majority of participants a former employee can remain a lead author if the publication is at or post internal review of drafts stage.
    2. For half of the participants, a former employee joining a competitor or IP sensitivity of the material can be a major barrier to keep this employee as a lead author.

METHODOLOGY


Best Practices, LLC engaged 23 leaders from biopharmaceutical companies and a publication services consultancy in this benchmarking research.


Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care


Companies Profiled:
Abbvie; Akebia Therapeutics; Allergan; Alnylam Pharmaceuticals; Astellas; AstraZeneca; Bayer; Bioventus; Celgene; Daiichi Sankyo; Envision Pharma Group; Ferring Pharmaceuticals; Genentech; Heel; Johnson & Johnson; Merck; Novartis; Roche; Sanofi Genzyme; Shionogi Inc.; Shire; Takeda Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.